Search company, investor...
LipoScience company logo


Founded Year



Acq - P2P | Acquired

Total Raised




About LipoScience

LipoScience is a diagnostic company utilizing nuclear magnetic resonance (NMR) spectroscopy to measure the size and quantity of lipoprotein particles in blood. The company's NMR LipoProfile blood test is intended to provide a better indication of the risk of developing cardiovascular heart disease than the standard cholesterol test measurements of 'good' and 'bad' cholesterol. The company currently markets and sells the NMR LipoProfile test to physicians, other healthcare professionals, diagnostic laboratories and clinical research clients.

Headquarters Location

700 Spring Forest Road Suite 100

Raleigh, North Carolina, 27609,

United States


Missing: LipoScience's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: LipoScience's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing LipoScience

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

LipoScience is included in 1 Expert Collection, including Medical Devices.


Medical Devices

3,088 items

Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)

LipoScience Patents

LipoScience has filed 39 patents.

The 3 most popular patent topics include:

  • Nuclear magnetic resonance
  • Blood tests
  • Diabetes
patents chart

Application Date

Grant Date


Related Topics




Blood, Body fluids, Blood products, Transfusion medicine, Hematology


Application Date


Grant Date



Related Topics

Blood, Body fluids, Blood products, Transfusion medicine, Hematology



Latest LipoScience News

Statin initiation may lower mortality risk in older veterans

Jul 7, 2020

Disclosures: Orkaby and Nelson report no relevant financial disclosures. Nicholls reports he received a principal research fellowship from the National Health and Medical Research Council of Australia; received research support from Amgen, Anthera, AstraZeneca, Cerenis, Eli Lilly, InfraReDx, LipoScience, The Medicines Company, Novartis, Resverlogix, Roche and Sanofi-Regeneron, and received consultant fees and honoraria from Anthera, AstraZeneca, Boehringer Ingelheim, CSL Behring, Eli Lilly, Esperion, Merck, Omthera, Resverlogix, Sanofi-Regeneron and Takeda. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact . Back to Healio Statin initiation in older U.S. veterans free from atherosclerotic CVD at baseline reduced the risk for CV and all-cause mortality, researchers found in a retrospective cohort study. “In this retrospective analysis, we found that the risk of dying from any cause was lower by 25% among veterans who were newly prescribed a statin compared with those who were not treated with statins,” Ariela R. Orkaby, MD, MPH, geriatrician and researcher at the VA Boston Health Care System and in the division of aging at Brigham and Women’s Hospital and Harvard Medical School, told Healio. “The risk of dying from a cardiovascular event such as a heart attack or stroke was lower by 20%. Secondarily, the risk of an overall cardiovascular event, including heart attacks, strokes , coronary bypass surgery or coronary catheterization, was 8% lower in those prescribed a statin compared with those who were not prescribed a statin.” Source: Adobe Stock. Older patients without ASCVD In this study published in JAMA, researchers analyzed data from 326,981 patients (mean age, 81 years; 97% men) aged 75 years and older who regularly used U.S. Veterans Affairs services between 2002 and 2012. All patients were free from ASCVD at baseline, defined as a history of transient ischemic attack or stroke, MI, coronary revascularization or peripheral vascular disease. No patients were taking statins at entry into the cohort but were monitored for initiation throughout the study. The primary outcomes for this study were CV and all-cause mortality . Secondary outcomes included ischemic stroke, MI, revascularization and a composite of these ASCVD events. From baseline, new statin users accounted for 17.5% of the patient population in this study. There were 206,902 deaths including 53,296 CV deaths during a mean follow-up of 6.8 years. This equaled to 78.7 total deaths per 1,000 person-years in patients taking statins compared with 98.2 total deaths per 1,000 person-years in those not taking statins before adjustment (weighted incidence rate difference per 1,000 person-years, 19.5; 95% CI, 20.4 to 18.5). For CV deaths, there were 22.6 deaths per 1,000 person-years in the statin group vs. 25.7 deaths per 1,000 person-years in the nonstatin group (weighted incidence rate difference per 1,000 person-years, 3.1; 95% CI, 3.6 to 2.6). During follow-up, there were 123,379 composite ASCVD events. This equated to 66.3 events per 1,000 person-years in patients taking statins compared with 70.4 events per 1,000 person-years in those not taking the medications (weighted incidence rate difference per 1,000 person-years, 4.1; 95% CI, 5.1 to 3). PAGE BREAK Researchers applied propensity score overlap weighting to this data, which showed that statin use was significantly linked to a lower risk for CV death (HR = 0.8; 95% CI, 0.78-0.81) and all-cause mortality (HR = 0.75; 95% CI, 0.74-0.76) when compared with those not taking statins. The HR for a composite of ASCVD events was 0.92 when comparing these two groups (95% CI, 0.91-0.94). Ariela R. Orkaby “Age alone should not be a reason not to prescribe a statin to older adults,” Orkaby said in an interview. Orkaby added that more research is needed in this area. She said, “Although real-world, carefully conducted epidemiologic studies like this one are very useful to further our understanding of the role of statins for cardiovascular prevention, we still need clinical trials, the gold standard of evidence. An exciting new trial called PREVENTABLE will soon begin enrolling participants [aged at least 75 years] across the U.S. to help us further understand the role of statins in this age group.” ‘Fastest-growing population subgroups’ Stephen J. Nicholls In a related editorial, Stephen J. Nicholls, MBBS, PhD, director of Monash Heart and professor at Monash University in Melbourne, Australia, and Adam J. Nelson, MBBS, PhD, postdoctoral cardiology fellow at Duke Clinical Research Institute, North Carolina, wrote: “The findings of the study by Orkaby et al provide additional support for treatment guidelines that have increasingly advocated for more widespread use of statin therapy for ASCVD prevention in older individuals. While randomized trials will provide the most definitive data to support these recommendations, observational data from large cohorts have the potential to guide clinical practice in the interim. Because patients older than 75 years represent one of the fastest-growing population subgroups in health care systems, there is a major need to provide an evidence base that informs use of therapies that are both safe and efficacious, in a cost-effective manner.” Reference:

LipoScience Frequently Asked Questions (FAQ)

  • When was LipoScience founded?

    LipoScience was founded in 1994.

  • Where is LipoScience's headquarters?

    LipoScience's headquarters is located at 700 Spring Forest Road, Raleigh.

  • What is LipoScience's latest funding round?

    LipoScience's latest funding round is Acq - P2P.

  • How much did LipoScience raise?

    LipoScience raised a total of $49.82M.

  • Who are the investors of LipoScience?

    Investors of LipoScience include LabCorp, Three Arch Partners, Pappas Ventures, SightLine Partners, Invesco Private Capital and 11 more.

  • Who are LipoScience's competitors?

    Competitors of LipoScience include Integrated Diagnostics, ContraVac, VidiStar, CardioDx, NanoMR and 14 more.

Compare LipoScience to Competitors

iMMCO Diagnostics

IMMCO Diagnostics provides high-quality diagnostic test kits and lab testing services worldwide for the screening of autoimmune disorders. IMMCO Diagnostics incorporates working on research, clinical laboratory expertise, and medical devices into an approach to autoimmune diagnostics.


Adlyfe was established to develop technologies for testing for early targets of amyloid diseases. Adlyfe is developing a test for the detection of amyloid proteins as early biomarkers of fatal brain diseases. The company's technology is based on the synthesis of small peptide ligands (Pronucleon ligands) which are amino acid sequence matched to target amyloids of interest. Ligand sequences are selected based on regions of the target protein known to undergo conformational changes associated with amyloid formation. Ligand sequence selection is the basis for diagnostic specificity. The interaction of the target amyloid protein with its ligands induces the ligands to undergo a conformational change that transduces a fluorescent signal or form an association with the target that can be detected. Further amplification of the signal is generated as additional ligands are nucleated to undergo conformational changes. This is the basis for sensitivity and ability to detect very low amyloid protein levels before symptoms occur.


Kjaya is a company that received a SBIR Phase I grant for a project entitled: Semi-Autonomous Adaptive Neural and Genetic Segmentation of Medical Images. Their Phase I project will implement a physician-assisted, real-time adaptive system for the segmentation of anatomical structures in 3D medical image data. Medical image segmentation seeks to change the representation of an anatomical structure, making it more easily analyzed. Because of the extreme variability of these structures in biological systems, current idiosyncratic manual methods currently in use are tedious, time consuming, and error prone. Image segmentation cannot in general be programmatically solved. The proposed system is a Neural Network (NN) based adaptation of the individual data using parallel Graphics Processing Units (GPUs) and coupled with a Genetic Algorithm (GA) based adaptation across GPU cores. The system will build a diagnostically useful segmentation of the anatomical feature within seconds from an area of interest outlined by a physician using a Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Fast growth in medical imaging overwhelms available diagnosticians. An intuitive and inexpensive system to quickly and accurately deliver diagnostic relevant segmentation of medical images offers tremendous commercial value. Currently, each scan requires approximately 50 minutes of manual preparation. The diagnosis and treatment of an estimated 20 percent of diseases benefit from medical imaging. Newer scanning technologies have increased in resolution, but such techniques have not made segmenting easier or faster. The proposed method will enable more diagnostics to be done with the quality controlled directly by physicians.

Daktari Diagnostics Logo
Daktari Diagnostics

Daktari Diagnostics develops products that deliver critical diagnostic information to clinicians and patients. Daktari's initial product is a handheld CD4 cell counter that aims to enable CD4 counting to be done by anyone. The company intends to bring this blood test to parts of the world where millions of people now have access to life-saving drugs, yet cannot begin treatment due to inadequate diagnostics.


Sentinel Diagnostics is an Italian company with a long and well established background in the development and production of diagnostic kits destined for use in medical analysis laboratories, hospitals, clinics and private health care structures.

LifeLineLab S.r.l.

Lifelinelab s.r.l. started its activities in April 2003, thanks to the commitment of three managers coming from the ex Diagnostic Division Manufacturing Plant of Alfa Wassermann S.P.A. First step has been to secure raw materials, and equipment for R&D and Manufacturing of products and services in the field of Human in Vitro Diagnostics. nnnnnFirst diagnostic reagents were manufactured, in this site, over 40 years ago, through the bravery and the enterprising spirit of Prof. Balducci ex Managing Director of Virology Laboratory of "Istituto Superiore di Sanitu00e0". First products were based on tissue colture technology included a line of complement fixation antigens. Since then, the company developed methods and products, covering almost all the fields of Human in Vitro Diagnostics, from Clinical Chemistry to Immunochemistry. The mostly developed sector has been that of Infectious Diseases with particular regard to Viral pathologies. Most products have been developed using biological raw materials derived from in house, in vivo or in vitro, productions. Nowadays the company aims to face and develop markets with consolidate and emerging technologies such as Microarrays using a chemistry patented and designed to covalently bind either Protein or Nucleic acids which aims to allow the development of extremely sophisticated analysis in the emerging applications of proteomics and genomics.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.